Tag «Antineoplastic»

Lead (212Pb) bamzireotide navoxetan

Lead (212Pb) bamzireotide navoxetan CAS 2941523-47-1 MF C72H104N16O20212PbS2 MW1789.8 g/mol 2-[4-[2-[2-[2-[3-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-oxopropoxy]ethoxy]ethylamino]-2-oxoethyl]-10-(2-amino-2-oxoethyl)-7-(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;lead-212(2+) ANTINEOPLASTIC, D2A42X3LCS SYN US 11037690 B2 AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT join me on Linkedin Anthony Melvin Crasto Ph.D – India | LinkedIn join me on Researchgate RESEARCHGATE join me on Facebook Anthony Melvin Crasto Dr. | Facebook join me on twitter …

Pebezertinib

Pebezertinib CAS 2769954-39-2 MF C24H19F4N7O MW 497.4 g/mol N-[4-fluoro-3-[[2-[(1-methylpyrazol-4-yl)amino]-5-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]amino]phenyl]prop-2-enamide N-[4-fluoro-3-({2-[(1-methyl-1H-pyrazol-4-yl)amino]-5-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl}amino)phenyl]prop-2-enamideepidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, antineoplastic, BLU 451, BLU 203139, G8G5AU5GLJ, LNG 451 Pebezertinib is a small molecule drug. The usage of the INN stem ‘-ertinib’ in the name indicates that Pebezertinib is a epidermal growth factor receptor (EGFR) inhibitor. Pebezertinib is under investigation …

Orenasitecan

Orenasitecan CAS 2418533-89-6 MF C72H86N12O20S MW1471.59 (3S)-3-[3-[2-[2-[2-[[4-[[(1R)-2-carboxy-1-[3-[[3-(propylcarbamoylamino)phenyl]sulfonylamino]phenyl]ethyl]carbamoylamino]phenyl]carbamoylamino]ethoxy]ethoxy]ethoxy]propanoylamino]-4-[(2S)-2-[[(2S)-1-[[(19S)-10,19-diethyl-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl]oxy]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxobutanoic acid (4S)-4,11-diethyl-3,14-dioxo-3,4,12,14-tetrahydro-1Hpyrano[ 3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl N-{1-[4-({[(1R)-2-carboxy-1-(3-{3-[(propylcarbamoyl)amino]benzene-1-sulfonamido}phenyl)ethyl]carbamoyl}amino)anilino]-1-oxo-5,8,11-trioxa-2-azatetradecan-14-oyl}-L-alpha-aspartyl-L-prolyl-L-valinate (4S)-4,11-diethyl-3,14-dioxo-3,4,12,14-tetrahydro-1Hpyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl N-{1-[4-({[(1R)-2-carboxy-1-(3-{3-[(propylcarbamoyl)amino]benzene-1-sulfonamido}phenyl)ethyl]carbamoyl}amino)anilino]-1-oxo-5,8,11-trioxa-2-azatetradecan-14-oyl}-L-α-aspartyl-L-prolyl-L-valinateantineoplastic, L3KV5NR5PG Orenasitecan is a small molecule drug. The usage of the INN stem ‘-tecan’ in the name indicates that Orenasitecan is a antineoplastic, topoisomerase I inhibitor. Orenasitecan has a monoisotopic molecular weight of 1470.58 Da. ORENASITECAN is a small molecule drug with …

Olomorasib

Olomorasib CAS 2771246-13-8 MF C25H19ClF2N4O3S MW528.96 4-[(13aS)-10-chloro-8-fluoro-6-oxo-2-prop-2-enoyl-1,3,4,12,13,13a-hexahydropyrazino[2,1-d][1,5]benzoxazocin-9-yl]-2-amino-7-fluoro-1-benzothiophene-3-carbonitrile Benzo[b]thiophene-3-carbonitrile, 2-amino-4-[(4aS)-8-chloro-10-fluoro-2,3,4,4a,5,6-hexahydro-12-oxo-3-(1-oxo-2-propen-1-yl)-1H,12H-pyrazino[2,1-d][1,5]benzoxazocin-9-yl]-7-fluoro-, (4R)- (4M)-2-amino-4-[(4aS)-8-chloro-10-fluoro-12-oxo-3-(prop-2-enoyl)-2,3,4,4a,5,6-hexahydro-1H,12H-pyrazino[2,1-d][1,5]benzoxazocin-9-yl]-7-fluoro-1-benzothiophene-3-carbonitrileKirsten rat sarcoma viral oncogene homolog (KRAS) inhibitor, antineoplastic, LY3537982, LY 3537982, KRAS-G12C-II, LY-3537982, C2VJ83PSN7, Olomorasib (LY3537982) is an investigational, oral, second-generation KRAS G12C inhibitor designed to treat advanced solid tumors, particularly non-small cell lung cancer (NSCLC). Developed by Eli Lilly and Company, it shows promising antitumor …

Naxtarubicin, Annamycin

Naxtarubicin, Annamycin CAS 92689-49-1 MF C26H25IO11 MW 640.4 g/mol 2′-Iodo-3′-hydroxy-4′-epi-4-demethoxydoxorubicin (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione (7S,9S)-7-[(2,6-dideoxy-2-iodo-α-L-mannopyranosyl)oxy]-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dioneDNA topoisomerase II inhibitor, antineoplastic, Annamycin, Annamycin-LF, Annamycin-liposomal, L-ANNA, L-annamycin, Liposomal annamycin, S-ANNA, SNU299M83Q Naxtarubicin is a lipophilic, anthracycline antineoplastic antibiotic.Naxtarubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and repair as well as inhibiting RNA and protein synthesis. This agent appears …

Mosperafenib

Mosperafenib CAS 2649372-20-1 MF C20H17F2N5O4S MW 461.4 g/mol (3R)-N-{2-cyano-4-fluoro-3-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}-3-fluoropyrrolidine-1-sulfonamideB-Raf (BRAF) inhibitor, antineoplastic, RG6344, RO7276389, RG 6344, RO 7276389, 881-730-4, B-Raf IN 2 Mosperafenib is a small molecule drug. The usage of the INN stem ‘-rafenib’ in the name indicates that Mosperafenib is a Raf (rapidly accelerated fibrosarcoma) kinase inhibitor. Mosperafenib has a monoisotopic molecular weight of …

Mocaciclib

Mocaciclib CAS 2766124-39-2 MF C33H36FN9O2 MW609.71 cyclin-dependent kinase (CDK) inhibitor, antineoplastic, Q 901, CDK7-IN-21, Mocaciclib (Q-901) is an orally bioavailable, selective cyclin-dependent kinase (CDK) inhibitor with potent activity against CDK2, CDK4, and CDK6. Preclinical data show that Mocaciclib inhibits CDK2/cyclin E with an IC₅₀ of 1.1 nM, CDK4/cyclin D1 with an IC₅₀ of 2.5 nM, …

Mobinitinib

Mobinitinib CAS1402709-93-6 MF C22H23Cl2N7 MW456.37 6-chloro-7-{4-[(4-chlorophenyl)methyl]piperazin-1-yl}-2-(1,3-dimethyl-1Hpyrazol-4-yl)-3H-imidazo[4,5-b]pyridine 6-chloro-7-{4-[(4-chlorophenyl)methyl]piperazin-1-yl}-2-(1,3-dimethyl-1Hpyrazol-4-yl)-3H-imidazo[4,5-b]pyridinedual FMS-like tyrosine kinase-3 (FLT3)-Aurora kinase inhibitor, antineoplastic, CCT241736, CCT 241736, ZE94SP78UG, EP0042, EP 0042 Mobinitinib (CCT241736) is an investigational, orally bioavailable, small-molecule, dual inhibitor targeting Aurora kinase and FLT3 (including ITD and D835Y mutations). It shows potent antineoplastic activity in preclinical models, including acute myeloid leukemia (AML), by inhibiting tumor …

Mevrometostat

Mevrometostat CAS 1844849-10-0 MF C22H24Cl2N2O5 MW467.3 g/mol 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one 5,8-dichloro-7-[(R)-methoxy(oxetan-3-yl)methyl]-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-oneenhancer of zeste homolog 2 (EZH2) inhibitor, antineoplastic, PF-06821497, PF 06821497, S4L4MM20B6 Mevrometostat (development code PF-06821497) is an investigational anticancer drug that functions as a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2).[1][2] Currently under development by Pfizer, mevrometostat is being investigated primarily for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in …

Luvometinib

Luvometinib CAS 2739690-43-6 MF C26H22F2IN5O4S MW665.5 g/mol CHINA 2025, APPROVALS 2025 N-[3-[6-cyclopropyl-3-fluoro-4-(2-fluoro-4-iodoanilino)-1-methyl-2,5-dioxopyrido[2,3-d]pyridazin-8-yl]phenyl]cyclopropanesulfonamide N-{3-[6-cyclopropyl-3-fluoro-4-(2-fluoro-4-iodoanilino)-1-methyl-2,5-dioxo-1,2,5,6-tetrahydropyrido[2,3-d]pyridazin-8-yl]phenyl}cyclopropanesulfonamidemitogen-activated protein kinase (MEK) inhibitor, antineoplastic, FCN 159, FCN-159, B2DYT4V89X Luvometinib is a drug for the treatment of various types of cancer. It is a selective, orally administered inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/MEK2), developed by Fosun Pharma for the treatment of rare malignancies, especially …